Maris Hartmanis new BioPhausia CEO

Maris Hartmanis new BioPhausia CEO

The Board of BioPhausia has appointed Maris Hartmanis as the Company's new CEO. He takes up his position on 9 August, and succeeds Claes Thulin who has decided to pursue his own entrepreneurial activities after serving eight years as CEO.

Maris Hartmanis will be working in parallel with Claes Thulin during May and June. Maris Hartmanis is 56 years of age and has many years of experience inleading positions in companies in the biotechnology, medical technology and pharmaceutical industries. He was Senior Vice President of R&D at Gambro between 2004 and 2008 and has held positions in Gyros,Amersham Biosciences, Pharmacia & Upjohn, Pharmacia and KabiGen.

"We are delighted to have recruited a new CEO with such in-depth and extensiveexperience in different areas of the Life Science industry," says BioPhausia'sChairman of the Board Jan Rynning. "We are convinced that Maris has theexpertise and background required to take BioPhausia into the next phase of itsdevelopment.""BioPhausia is a very interesting company and I look forward to helping continuethe successful growth strategy," says Maris Hartmanis. "I am certain that thepharmaceutical market niche which BioPhausia occupies has excellent scope fordevelopment."

Suggested Articles

Cedrik Britten, M.D., becomes the biotech’s new chief medical officer to help run its adoptive cell therapy and TCR bispecifics platform.

Five Prime Therapeutics’ clinical development lead is hoping for a more stable time at new employer Spectrum Pharma.

The update comes as Gilead closes in on a FDA approval that will position it to compete with JAK inhibitors sold by AbbVie, Eli Lilly and Pfizer.